Brief: Achilles Therapeutics Doses First Patient With Higher-Dose Cnet In Phase I/Iia Chiron Trial In Advanced Nsclc
09/05/2022 12:05
May 9 (Reuters) - Achilles Therapeutics PLC 698y.F :
* ACHILLES THERAPEUTICS DOSES FIRST PATIENT WITH HIGHER-DOSE
CNET
IN PHASE I/IIA CHIRON TRIAL IN ADVANCED NSCLC AND INITIATES
ENROLLMENT IN COHORT B OF THE THETIS TRIAL (CNET + PD-1
CHECKPOINT INHIBITOR) IN METASTATIC MALIGNANT MELANOMA
* ACHILLES THERAPEUTICS PLC - MONOTHERAPY DATA FROM
HIGHER-DOSE
COHORTS IN CHIRON AND THETIS, COMBINATION DATA FROM THETIS
COHORT B EXPECTED IN 2H 2022
Source text for Eikon: ID:nGNX2V9WHz
Further company coverage: 698y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achilles Therapeutics
See all newsBrief: Achilles Therapeutics Announces Sale Of Technology Assets To Astrazeneca
Brief: Achilles Therapeutics Receives Approval To Transfer To Nasdaq Capital Market
Achilles gains on plans to explore strategic options
Brief: Achilles Therapeutics To Discontinue Development Of TIL-Based cNET Therapy
Brief: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement